Binnopharm Group has secured registration for Lorothricin-Alium, a combination medication for sore throat, with sales in Kyrgyz Republic slated to begin in March 2025. This drug will broaden the company’s anti-cold product line in the Republic, which already features well-known brands like Kagocel (managed by Binnopharm Group), Elmucin, and Prostudox.
According to a company statement, “When introducing drugs to new markets, we prioritize current patient needs and product relevance. Lorothricin-ALIUM has rapidly gained traction in the Russian Federation. In the two years since its introduction to the domestic market, 3 million packages have been sold. The drug demonstrated robust growth of +294% in package sales and +325% in ruble terms in 2024 compared to the previous year.”
Lorothricin-ALIUM is manufactured at the Alium plant located in Obolensk, Moscow region. This facility produces both prescription and over-the-counter medications across various therapeutic areas, including pulmonology, neurology, cardiology, gastroenterology, infectious diseases and cold remedies, phlebology, urology, antibiotics and antiseptics, and pain management. The plant is designed to fully comply with GMP standards and is equipped with advanced technology. In 2024, the facility produced 64.6 million packages of drugs.
